As of November 7, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Keros Therapeutics, Inc. The largest reported stake is BlackRock Portfolio Management LLC's, at 9.1%. 17 filings are on record since August 21, 2025 (Schedule 13G/A, October 27, 2026).
Who owns Keros Therapeutics, Inc.?
Sell to companies like Keros Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock Portfolio Management LLC · Sole voting: 1,575,150 · Shared voting: 0 · Sole dispositive: 1,813,870 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
- · Reporting person: BlackRock, Inc. · Sole voting: 1,645,352 · Shared voting: 0 · Sole dispositive: 1,671,343 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-29
- · Holder: BlackRock Portfolio Management LLC · Percent: 5.7% · SCHEDULE 13G
- · Holder: Nantahala Capital Management, LLC · Percent: 6.9% · SCHEDULE 13G
- · Holder: BlackRock, Inc. · Percent: 10.1% · SCHEDULE 13G
Keros Therapeutics, Inc. has 17 Schedule 13D or 13G filings on record since 2025-08-21. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock Portfolio Management LLC | 9.1% | 1,813,870 | SCHEDULE 13G/A, 2026-10-27 | 2026-09-30 |
| BlackRock, Inc. | 8.4% | 1,671,343 | SCHEDULE 13G/A, 2026-07-29 | 2026-06-30 |
| Nantahala Capital Management, LLC | 6.9% | 1,360,419 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| D. E. Shaw & Co., L.P. | 3.9% | 756,156 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Madison Avenue International LP | 2.7% | 823,707 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| ExodusPoint Capital Management, LP | 0.04% | 13,360 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| ADAR1 Capital Management, LLC | 0% | 0 | SCHEDULE 13D/A, 2025-10-15 | 2025-10-15 |
| Pontifax Management 4 GP (2015) Ltd. | 0% | 0 | SCHEDULE 13D/A, 2025-10-16 | 2025-10-15 |
| Tang Capital Management, LLC | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Keros Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Keros Therapeutics, Inc. and the records around it.
Keros Therapeutics, Inc. elsewhere on the record
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- ExodusPoint Capital Management, LP also filed stake reports on 3 other companies: RE/MAX Holdings, Inc. (Aug 2026), SPRUCE BIOSCIENCES, INC. (Apr 2026), ALT5 Sigma Corp (Aug 2025)
- Pontifax Management 4 GP (2015) Ltd. also filed stake reports on 3 other companies: Agomab Therapeutics NV (Apr 2026), LB Pharmaceuticals Inc (Sep 2025), Climb Bio, Inc. (Sep 2025)
- Madison Avenue International LP also filed stake reports on 11 other companies: Ultragenyx Pharmaceutical Inc. (Oct 2026), Graham Holdings Co (Aug 2026), STAAR SURGICAL CO (Aug 2026)
Watch Keros Therapeutics, Inc.
Get an email when Keros Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Keros Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Keros Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Keros Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock Portfolio Management LLC | 1,575,150 | 0 | 1,813,870 | 0 | SCHEDULE 13G/A, 2026-10-27 |
| BlackRock, Inc. | 1,645,352 | 0 | 1,671,343 | 0 | SCHEDULE 13G/A, 2026-07-29 |
The latest filing identifies Keros Therapeutics, Inc. by CUSIP 492327101 and gives its principal executive office as 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA 02421 (SCHEDULE 13G/A, 2026-10-27).
Purpose of Transaction (Item 4)
ADAR1 Capital Management, LLC
Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following: On October 15, 2025, ADAR 1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC (the "ADAR1 Funds") and ADAR1 Capital Management (together with the ADAR1 Funds, the "ADAR1 Parties") entered into a stock purchase agreement (the "Stock Purchase Agreement") with the Issuer pursuant to which the ADAR1 Funds agreed to sell a total of 5,389,264 shares of Common Stock to the Issuer at a price equal to $17.75 per share, for an aggregate price of $95,659,436. The Stock Purchase Agreement also includes certain standstill provisions during the Standstill Period (as defined in the Stock Purchase Agreement), including, among other things, a restriction on the ability of the ADAR1 Parties to acquire an ownership interest of more than 4.9% of the outstanding shares of Common Stock. The foregoing description of the Stock Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Stock Purchase Agreement, the form of which is attached hereto as Exhibit I and is incorporated herein by reference.Item 4 of the SCHEDULE 13D/A filed 2025-10-15
Pontifax Management 4 GP (2015) Ltd.
Item 4 is hereby amended and supplemented with the addition of the following: On October 15, 2025, certain of the Reporting Persons (collectively, the "Pontifax Parties") and the Issuer entered into a Stock Purchase Agreement (the "Repurchase Agreement"). Pursuant to the Repurchase Agreement, the Pontifax Parties agreed to sell a total of 4,787,331 shares of Common Stock, representing all the shares of Common Stock owned by the Reporting Persons, at a per share price of $17.75, for an aggregate price of $84,975,125.25. Pursuant to the Repurchase Agreement, the Pontifax Parties also agreed to certain standstill restrictions and voting commitments during the Standstill Period (as defined in the Repurchase Agreement), including, among other things, a restriction on the ability of the Pontifax Parties to acquire more than 100,000 shares of Common Stock (subject to certain limited exceptions and adjustments). The Issuer and the Pontifax Parties have also agreed to certain mutual non-disparagement obligations that remain in effect during the Standstill Period. In addition, concurrently with the execution of the Repurchase Agreement, each of Tomer Kariv and Ran Nussbaum, affiliates of the Pontifax Parties, delivered their resignations from the Issuer's board of directors and all committees thereof. The foregoing description of the Repurchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Repurchase Agreement, which …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-10-16; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-21 | ADAR1 Capital Management, LLC | 13.27% | SCHEDULE 13D/A |
| 2025-10-15 | ADAR1 Capital Management, LLC | 0% | SCHEDULE 13D/A |
| 2025-10-16 | Pontifax Management 4 GP (2015) Ltd. | 0% | SCHEDULE 13D/A |
| 2025-10-22 | Tang Capital Management, LLC | 7.9% | SCHEDULE 13G |
| 2025-10-27 | D. E. Shaw & Co., L.P. | 5.1% | SCHEDULE 13G |
| 2025-11-18 | ExodusPoint Capital Management, LP | 6.3% | SCHEDULE 13G |
| 2026-01-30 | The Vanguard Group | 5% | SCHEDULE 13G/A |
| 2026-02-17 | ExodusPoint Capital Management, LP | 0.04% | SCHEDULE 13G/A |
| 2026-02-17 | Madison Avenue International LP | 2.7% | SCHEDULE 13G/A |
| 2026-02-17 | D. E. Shaw & Co., L.P. | 3.9% | SCHEDULE 13G/A |
| 2026-02-17 | Tang Capital Management, LLC | 0% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-07 | BlackRock, Inc. | 10.1% | SCHEDULE 13G |
| 2026-05-15 | Nantahala Capital Management, LLC | 6.9% | SCHEDULE 13G |
| 2026-07-17 | BlackRock Portfolio Management LLC | 5.7% | SCHEDULE 13G |
| 2026-07-29 | BlackRock, Inc. | 8.4% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock Portfolio Management LLC | 9.1% | SCHEDULE 13G/A |
Questions about who owns Keros Therapeutics, Inc.
Who owns Keros Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Keros Therapeutics, Inc.: BlackRock Portfolio Management LLC (9.1%, Schedule 13G/A, filed 2026-10-27), BlackRock, Inc. (8.4%, Schedule 13G/A, filed 2026-07-29) and Nantahala Capital Management, LLC (6.9%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Keros Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Keros Therapeutics, Inc. on this page are BlackRock Portfolio Management LLC (9.1%), BlackRock, Inc. (8.4%) and Nantahala Capital Management, LLC (6.9%).
When did BlackRock Portfolio Management LLC buy into Keros Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from BlackRock Portfolio Management LLC on this page is the Schedule 13G, filed 2026-07-17, reporting 5.7%; its latest, Schedule 13G/A filed 2026-10-27, reports 9.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Keros Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 22, 2026 | Leadership change: Keith Regnante departs, Chief Financial Officer, and 1 more | — | Leadership changes | Source |
| June 25, 2026 | Leadership change: Anne Prener appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Keros Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.